Diazoxide, an anti-hypertensive agent, has diverse pharmacologic effects; hypertrichosis, hyperglycemia associated with suppression of insulin release, and elevation of serum levels of androgens. Taking advantage of the hypertrichotic side effects of diazoxide, we examined the effect of topical application of the drug on hair regrowth in the bald frontal scalp of stumptailed macaques (Macaca arctoides); we also monitored systemic side effects. Using 7 adult stumptails, we applied diazoxide (5% solution in a vehicle) topically on the bald frontal scalp, once a day, 5 days per week. Two of seven macaques had vehicle alone applied. Hair growth was monitored by photographic recording (once every month) and by sequential analysis of folliculograms from biopsied skin (once every 4 months). We also examined body weight, hematology, blood pressure, heart rate, serum levels of testosterone and dihydrotestosterone, and glucose tolerance for a 4-month period. All 5 diazoxide-treated animals showed thickening and maintenance of the frontal hair during the entire treatment period (16 months). Analysis of folliculograms showed progressive enlargement of hair follicular size and acceleration of its cyclic growth from telogen to anagen phase and prolongation of anagen phase in all treated animals. Controls showed no consistent progressive changes of follicular growth. None of the animals treated with diazoxide showed abnormal changes in physical growth, cardiovascular function, serum levels of androgens, glucose tolerance (including insulin levels), or hematology
Diazoxide Anyone??? Effects Are Similar To Minoxidil
- Thread starter Warmer82
- Start date
What ever happened to this in 1986.
Abstract
DIAZOXIDE TOPICAL SOLUTION BEING DEVELOPED AS HAIR GROWTH PRODUCT by Lakatos-Topol Research Institute, the company announced in a Feb. 24 press release. Lakatos-Topol said it obtained an exclusive license to the product, except in Japan, from a physician in Detroit who developed a method to put diazoxide in solution. The original mfr. of diazoxide is Schering-Plough, which markets the drug in injectable form for treatment of hypertension under the brandname Hyperstat, and, at one time, marketed an oral formulation, called Proglycem, for management of hypoglycemia. Lakatos-Topol said Medical Market Specialties, Inc., located in Cedar Grove, N.J., currently markets Proglycem. Lakatos-Topol said it believes diazoxide is superior to Upjohn's Regaine (minoxidil) as a hair growth stimulant. The firm's release claims that diazoxide "produces a longer and thicker growth of hair" than the Upjohn product. Upjohn's minoxidil is also marketed as an antihypertensive under the tradename Loniten. Upjohn has an NDA pending for the topical dosage form for treatment of male pattern baldness and alopecia areata. Lakatos-Topol said it has begun testing the hair growth product outside the U.S. and requested FDA permission to conduct tests in the U.S. An IND has not yet been filed. The firm has also applied for a U.S. patent. Based in Houston, Texas, Lakatos-Topol was formed in July 1985 and went public in January. In its initial offering, the firm said it "intends to engage in cancer research and the business of research and development of diagnostic, treatment, and therapeutic products incorporating monoclonal antibodies created by means of hybridoma technology or 'cell fusions.'" Lakatos-Topol said it raised $125,000 from its initial offering and needs to raise an additional $2 mil. to carry out development of three projects. In addition to diazoxide, the company said it acquired an exclusive license, except in Japan, to monoclonal antibodies to malignant melanoma and monoclonal antibodies to squamous cell carcinoma and basal cell carcinoma. Lakatos-Topol also reported that it is developing monoclonal antibodies to LDHK (lactate dehydrogenase K), an enzyme that the firm said is found solely in cancer cells. In its filing, the company said it anticipates contracting for R&D and clinical testing and "subcontracting with and/or licensing established mfrs. for production and marketing of some, or possibly all, of its products."
Abstract
DIAZOXIDE TOPICAL SOLUTION BEING DEVELOPED AS HAIR GROWTH PRODUCT by Lakatos-Topol Research Institute, the company announced in a Feb. 24 press release. Lakatos-Topol said it obtained an exclusive license to the product, except in Japan, from a physician in Detroit who developed a method to put diazoxide in solution. The original mfr. of diazoxide is Schering-Plough, which markets the drug in injectable form for treatment of hypertension under the brandname Hyperstat, and, at one time, marketed an oral formulation, called Proglycem, for management of hypoglycemia. Lakatos-Topol said Medical Market Specialties, Inc., located in Cedar Grove, N.J., currently markets Proglycem. Lakatos-Topol said it believes diazoxide is superior to Upjohn's Regaine (minoxidil) as a hair growth stimulant. The firm's release claims that diazoxide "produces a longer and thicker growth of hair" than the Upjohn product. Upjohn's minoxidil is also marketed as an antihypertensive under the tradename Loniten. Upjohn has an NDA pending for the topical dosage form for treatment of male pattern baldness and alopecia areata. Lakatos-Topol said it has begun testing the hair growth product outside the U.S. and requested FDA permission to conduct tests in the U.S. An IND has not yet been filed. The firm has also applied for a U.S. patent. Based in Houston, Texas, Lakatos-Topol was formed in July 1985 and went public in January. In its initial offering, the firm said it "intends to engage in cancer research and the business of research and development of diagnostic, treatment, and therapeutic products incorporating monoclonal antibodies created by means of hybridoma technology or 'cell fusions.'" Lakatos-Topol said it raised $125,000 from its initial offering and needs to raise an additional $2 mil. to carry out development of three projects. In addition to diazoxide, the company said it acquired an exclusive license, except in Japan, to monoclonal antibodies to malignant melanoma and monoclonal antibodies to squamous cell carcinoma and basal cell carcinoma. Lakatos-Topol also reported that it is developing monoclonal antibodies to LDHK (lactate dehydrogenase K), an enzyme that the firm said is found solely in cancer cells. In its filing, the company said it anticipates contracting for R&D and clinical testing and "subcontracting with and/or licensing established mfrs. for production and marketing of some, or possibly all, of its products."
- Reaction score
- 69
Acquired Generalized Hypertrichosis Due to Diazoxide | Actas Dermo-Sifiliográficas
To the Editor:Hypertrichosis is defined as the excessive growth of hair on any part of the body.1 In hirsutism, on the other hand, the
www.actasdermo.org
- Reaction score
- 732
What the heck happened to this?